ACP-105 and Its Interactions With Other Substances
ACP-105 is a synthetic selective androgen receptor modulator (SARM) that exists only as a research chemical. It has never been approved for human use, and reliable human data are essentially absent. Because products labeled as SARMs are widely sold despite this, our editorial team reviews what is actually known about ACP-105 and the interactions that are plausible on mechanistic grounds — while being clear about the limits of that knowledge.
What ACP-105 is
ACP-105 is a non-steroidal compound that binds the androgen receptor, the same receptor that testosterone and dihydrotestosterone activate. Unlike anabolic steroids, SARMs are designed to act selectively — in theory stimulating muscle and bone more than the prostate or other tissues.
The compound originated in pharmaceutical research programs exploring SARMs for conditions such as muscle wasting and osteoporosis. Published information on ACP-105 specifically comes mainly from preclinical studies and pharmacology databases, not clinical trials.
Because it is an androgen receptor agonist, its expected biological effects overlap with those of testosterone, including potential suppression of the body's own hormone production. "Selectivity" demonstrated in animals does not guarantee a clean profile in humans.
It is important to stress the knowledge gap: there are no established human doses, no safety database, and no long-term outcome data for ACP-105. Anything stated about its effects in people is extrapolation.
Regulatory and legal status
No SARM, including ACP-105, is an approved medicine in the United States. The FDA has warned that SARMs are associated with serious safety concerns, including the potential to increase the risk of heart attack and stroke and to cause liver injury.
Selling SARMs as dietary supplements is not lawful, because they do not meet the definition of a dietary ingredient. Products are often marketed as "for research use only," a label that does not make human consumption legal or safe.
SARMs are prohibited at all times in sport under the World Anti-Doping Agency list, in category S1.2. Athletes have tested positive after using products that contained SARMs, sometimes without the substance being disclosed on the label.
In 2022, the US enacted the SARMs Control Act framework discussions, and enforcement against unapproved sales has increased. Legal status can vary by country, but nowhere is ACP-105 an approved therapeutic.
Why "interactions" are largely theoretical
Drug interaction knowledge normally comes from dedicated pharmacokinetic studies, clinical trials, and post-marketing reports. For an approved drug, regulators compile this into a label. ACP-105 has none of that.
As a result, any discussion of interactions is based on general principles: its expected action at the androgen receptor, likely metabolism by liver enzymes, and effects seen with the SARM class as a whole. These are reasonable starting points but cannot replace real data.
This uncertainty is itself a safety issue. When someone combines an unstudied compound with prescription drugs, neither they nor their doctor can predict the result, and standard interaction checkers will not list it.
The honest conclusion is that no one can give a reliable interaction profile for ACP-105. What follows is framed as plausible concerns, not established facts.
Plausible interactions by mechanism
Because ACP-105 activates the androgen receptor, the clearest theoretical interactions are with other hormonal agents. Combining it with anabolic steroids or testosterone would add androgenic load and could deepen suppression of natural hormone production.
- Other androgens or SARMs — additive androgenic effects and axis suppression.
- Drugs metabolized by the liver — SARMs have been linked to liver injury, so combining with other hepatotoxic drugs (including high-dose acetaminophen or certain statins) could compound risk.
- Anticoagulants and antiplatelet drugs — androgens can affect clotting factors and lipids; unpredictable effect.
- Insulin and glucose-lowering drugs — androgens may alter insulin sensitivity.
- Drugs that affect cholesterol — SARMs tend to lower HDL, which could worsen lipid profiles.
SARMs as a class have been reported to cause marked drops in HDL cholesterol and, in some cases, drug-induced liver injury presenting as jaundice. These are the most consistently described harms and could interact with pre-existing cardiovascular or liver risk.
There is also the hormonal rebound to consider. Suppression of the hypothalamic-pituitary-gonadal axis can leave users with low testosterone after stopping, and taking other hormonal drugs to counteract this adds further unstudied interactions.
None of this should be read as a guide to combining substances. The point is the opposite: the interaction landscape is unknown, and that unpredictability is a reason for caution.
Product quality and contamination
A recurring finding in independent analyses is that products sold as SARMs frequently do not contain what the label claims. A study published in JAMA found that many online SARM products were mislabeled, with some containing no active compound, others containing different drugs, and dosages differing substantially from the label.
| Issue found in analyses | Implication |
|---|---|
| Different SARM or drug than labeled | Unexpected effects and interactions |
| Unapproved stimulants or steroids present | Cardiovascular and doping risk |
| Dose much higher or lower than stated | Toxicity or no effect |
| No active ingredient | Wasted risk with no "benefit" |
Contamination multiplies the interaction problem: if a product labeled ACP-105 actually contains another SARM, a stimulant, or an anabolic steroid, the real interactions are with those undisclosed substances.
This also matters for anyone subject to drug testing. Athletes have faced sanctions after using mislabeled products, and WADA explicitly warns that contamination is not an accepted excuse.
For consumers, there is no reliable way to verify the contents of a research chemical at home, which is one more reason the compound sits outside responsible use.
Conclusions of the editorial team
ACP-105 is an experimental SARM without approval, human safety data, or a credible interaction profile.
The interactions that can be discussed are theoretical, driven by its androgen-receptor activity and the SARM class's links to liver injury and lipid changes.
Product mislabeling is common, meaning the true interactions a user faces may come from undisclosed ingredients rather than ACP-105 itself.
Readers may also want our articles on why testosterone does not recover after a cycle, enclomiphene contraindications, and the side-effect profile of injectable anabolic steroids.
References
- Van Wagoner RM, Eichner A, Bhasin S, Deuster PA, Eichner D. Chemical composition and labeling of substances marketed as selective androgen receptor modulators and sold via the internet. JAMA. 2017;318(20):2004–2010.
- US Food and Drug Administration. FDA in brief: FDA warns against using SARMs in body-building products. 2017.
- Barbara M, Dhingra S, Mindikoglu AL. Drug-induced liver injury associated with the use of selective androgen receptor modulators (SARMs). ACG Case Rep J. 2020;7(6):e00401.
- Solomon ZJ, Mirabal JR, Mazur DJ, et al. Selective androgen receptor modulators: current knowledge and clinical applications. Sex Med Rev. 2019;7(1):84–94.
- World Anti-Doping Agency. The Prohibited List: S1 Anabolic Agents. WADA, current edition.
- https://anabolicstoreja.net/
